Welcome to our dedicated page for Revvity SEC filings (Ticker: RVTY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Revvity, Inc.'s SEC filings document operating results, governance matters and capital-structure disclosures for a Massachusetts-incorporated life sciences and diagnostics company. Its 8-K reports furnish quarterly and annual financial results, preliminary performance updates, Regulation FD investor presentation materials and other material-event disclosures.
Proxy and annual-meeting filings describe director elections, auditor ratification, advisory executive-compensation votes and shareholder-approved bylaw amendments, including the ability of holders of 25% of the company's stock to call a special meeting. Other current reports identify registered securities, including RVTY common stock and 1.875% notes due 2026 listed on the New York Stock Exchange, as well as officer appointments and related governance changes.
EdgePoint Investment Group Inc. disclosed ownership of 6,789,660 shares of Revvity, Inc. common stock, representing 5.76% of the class. EdgePoint reports sole voting and dispositive power over 4,481,400 shares and shared voting and dispositive power over 2,308,260 shares. The filing states these shares are held on behalf of private investment funds and mutual fund trusts for which EdgePoint acts as investment manager and exercises investment discretion.
The statement affirms the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Revvity. The filing includes EdgePoint's Ontario address and is signed by Sayuri Childs, Chief Compliance Officer.
Janus Henderson Group plc reports a stake in Revvity, Inc. The filing shows Janus Henderson as a beneficial owner of roughly 7.2 million American Depositary Shares, representing 6.1% of the class. The filing specifies no sole voting or dispositive power and records the holdings as shared voting and shared dispositive power of approximately 7.2 million shares.
The statement also identifies certain indirect subsidiaries as investment advisers that hold these positions and includes a power of attorney authorizing named officers to make regulatory filings on the group's behalf. Two different share totals are presented within the document, both tied to the same 6.1% disclosure.
Revvity (RVTY) 10-Q – Q2 FY25 highlights
Total revenue rose 4% YoY to $720.3 m, with Life Sciences +5% and Diagnostics +3%. 1H revenue reached $1.39 bn (+3%). Gross margin slipped 123 bp to 54.5% as tariffs and mix offset price increases. SG&A efficiencies trimmed opex, lifting operating income 6% to $90.8 m and widening operating margin 20 bp to 12.6%.
Profitability
- Income from continuing ops fell 24% to $55.2 m; net income dipped 3% to $53.9 m due to lower discontinued-ops losses.
- Diluted EPS held at $0.46 (net) as a 5% share count reduction offset lower earnings.
Cash & Balance Sheet
- Operating cash flow from continuing ops declined 19% to $268.4 m; FCF after capex ≈ $233 m.
- Cash fell to $991.8 m (-15%) after $447.5 m of buybacks and $16.7 m of dividends.
- Long-term debt increased to $3.21 bn; net cash/(debt) now ≈ -$2.22 bn.
Capital returns
- Repurchased 4.43 m shares YTD for $443 m; $414.5 m remains on the $1 bn program.
- Quarterly dividend maintained at $0.07.
Other items: Intangible amortization $85.3 m; FX translation pushed OCI positive by $159 m; no goodwill impairments. Management warns FY25 gross profit could be cut ~$20 m by tariffs despite mitigation efforts.
Takeaway: Top-line momentum is steady and cost control improving operating margin, but core earnings, cash generation and gross margin are under pressure. Heavy buybacks temper EPS erosion while leverage inches higher.